Corvus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 28
- Market Cap
- $254.5M
- Website
- http://www.corvuspharma.com
- Introduction
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Conditions
- Systemic Anaplastic Large Cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaLymphoma, T-Cell, PeripheralFollicular T-Cell LymphomaNodal Peripheral T-Cell Lymphoma With TFH PhenotypeLymphoma, T-Cell
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06561048
- Locations
- 🇺🇸
Corvus Pharmaceuticals, South San Francisco, California, United States
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT06345404
- Locations
- 🇺🇸
Corvus Clinical Trials Information, South San Francisco, California, United States
CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients
- Conditions
- Covid-19
- Interventions
- Drug: CPI-006 2 mg/kg + SOCDrug: CPI-006 1 mg/kg + SOCDrug: Placebo + SOC
- First Posted Date
- 2021-02-02
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04734873
- Locations
- 🇺🇸
Torrance Memorial Medical Center, Torrance, California, United States
🇵🇪Hospital Central Fuerza Aérea del Perú, Miraflores, Lima, Peru
🇵🇪Hospital María Auxiliadora, San Juan De Miraflores, Lima, Peru
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04464395
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸El Centro Regional Medical Center, El Centro, California, United States
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-02-21
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT04280328
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT03952078
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Seoul, Gyeonggido, Korea, Republic of
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇦🇺Epworth Healthcare, Melbourne, Victoria, Australia
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
- Conditions
- Cervical CancerOvarian CancerNon-Small Cell Lung CancerColorectal CancerSarcomaRenal Cell CancerBladder CancerTriple Negative Breast CancerPancreatic CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2018-03-06
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 117
- Registration Number
- NCT03454451
- Locations
- 🇺🇸
The John Hopkins University, Baltimore, Maryland, United States
🇦🇺Lifehouse, Camperdown, New South Wales, Australia
🇺🇸NY Hematology, Albany, New York, United States
Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects
- Conditions
- Healthy Subjects
- Interventions
- Drug: CPI-444 CapsulesDrug: CPI-444 Tablets
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03237988
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
- Conditions
- Renal Cell CancerMetastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2016-01-14
- Last Posted Date
- 2021-08-30
- Lead Sponsor
- Corvus Pharmaceuticals, Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT02655822
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada